Lexeo Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 58
- Market Cap
- $365.3M
- Website
- http://www.lexeotx.com
- Introduction
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Predicting 2025's biggest innovations in drug discovery
Biotech and pharma leaders predict 2025 innovations: personalized genetic treatments for cardiac and neurological diseases, advancements in fluorescent-guided surgery for nerve preservation, scaling CAR T cell therapy for chronic diseases, AI transforming clinical trials and regulatory processes, increased diversity in clinical trials, and progress in cell therapy for solid tumors.
Lexeo files $100m IPO in tough listing environment
Lexeo Therapeutics, focusing on AAV gene therapy, aims to raise $100M in its IPO, pricing shares at $11. Its lead program, LX2006, targets Friedreich’s ataxia cardiomyopathy, with $45M allocated. LX2020 for PKP2-ACM and an Alzheimer’s therapy are also funded, alongside preclinical candidates. Sarepta Therapeutics invested in Lexeo’s cardiovascular gene therapy programs.
Avista Therapeutics Appoints Steven Altschuler, MD, as Chairman of the Board
Avista Therapeutics appoints Steven Altschuler, MD, as Chairman of the Board, leveraging his extensive experience in gene therapy and healthcare to advance innovative treatments for retinal diseases using the scAAVengr platform.
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics, Inc. announced CEO R. Nolan Townsend will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The event will be webcast live and available for replay. Lexeo focuses on genetic medicine for cardiovascular diseases and APOE4-associated Alzheimer’s disease.
Gene therapy could treat Alzheimer's disease
Alzheimer’s disease research shifts focus from amyloid hypothesis to gene therapy, aiming to convert bad genetics to good in the brain. Researchers use viral vectors to deliver protective genes, like APOE2, to combat Alzheimer’s. Early results show promise, with decreased tau protein levels and no significant adverse events. Challenges include immune response to AAV vectors and therapy affordability.
Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034
DelveInsight's report on the Gene and Cell Therapies Targeting CNS Disorders market forecasts growth to 2034, highlighting key companies and therapies, including Bayer AG's Phase Ib clinical trial success for Parkinson's disease and uniQure's positive trends in Huntington's disease trials. The market, valued at approximately USD 1 billion in 2021, is expected to surge due to increasing disease prevalence and pipeline product launches.
How decentralisation can fill the gaps in Alzheimer's research
New Alzheimer's therapies like Kisunla and Leqembi face regulatory and access challenges, highlighting the need for balancing clinical rigor with patient convenience. Decentralised trials (DCTs) are crucial for Alzheimer's research, though their use has declined, with Eli Lilly leading in DCT adoption. Digital health technologies, including telemedicine and wearables, offer potential to enhance trial data quality and patient recruitment, but challenges remain in ensuring technology usability and data integrity.
© Copyright 2025. All Rights Reserved by MedPath